Zeleris

Negara: Uni Eropa

Bahasa: Inggris

Sumber: EMA (European Medicines Agency)

Beli Sekarang

Selebaran informasi Selebaran informasi (PIL)
30-05-2017
Karakteristik produk Karakteristik produk (SPC)
30-05-2017

Bahan aktif:

florfenicol, meloxicam

Tersedia dari:

CEVA Santé Animale

Kode ATC:

QJ01BA99

INN (Nama Internasional):

florfenicol, meloxicam

Kelompok Terapi:

Cattle

Area terapi:

Amphenicols, combinations, Antibacterials for systemic use

Indikasi Terapi:

For therapeutic treatment of bovine respiratory disease (BRD) associated with pyrexia due to Mannheimia haemolytica, Pasteurella multocida and Histophilus somni susceptible to florfenicol.

Status otorisasi:

Authorised

Tanggal Otorisasi:

2017-05-15

Selebaran informasi

                                16
B. PACKAGE LEAFLET
17
PACKAGE LEAFLET
ZELERIS 400 MG/ML + 5 MG/ML
SOLUTION FOR INJECTION FOR CATTLE
1.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF
THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH
RELEASE, IF DIFFERENT
Marketing authorisation holder and manufacturer responsible for batch
release:
Ceva Santé Animale
10 av. de La Ballastière
33500 Libourne
FRANCE
2.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Zeleris 400 mg/ml + 5 mg/ml solution for injection for cattle
florfenicol / meloxicam
3.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
1 ml contains 400 mg of florfenicol and 5 mg of meloxicam.
Clear yellow solution.
4.
INDICATION
For therapeutic treatment and of bovine respiratory disease (BRD)
associated with pyrexia due to
_Mannheimia haemolytica_
,
_Pasteurella multocida _
and
_Histophilus somni_
susceptible to florfenicol.
5.
CONTRAINDICATIONS
Do not use in adult bulls intended for breeding.
Do not use in animals suffering from impaired hepatic, cardiac or
renal function and haemorrhagic
disorders, or when there is evidence of ulcerogenic gastrointestinal
lesions.
Do not use in case of hypersensitivity to the active substances or to
any of the excipients.
6.
ADVERSE REACTIONS
Injection site reactions (mostly swelling, induration, heat and pain)
were very commonly observed
after subcutaneous administration of the product. These effects were
transitory and usually resolved
without any treatment within 5 to 15 days, but could persist up to 49
days.
During injection of this product animals may exhibit signs of moderate
pain, manifested as movement
of the head or neck.
The frequency of adverse reactions is defined using the following
convention:
- very common (more than 1 in 10 animals treated displaying adverse
reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals
treated)
- rare (more than 1 but less than 10 animals in 10,000 animals
treated)
- very rare (less than 1 a
                                
                                Baca dokumen lengkapnya
                                
                            

Karakteristik produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Zeleris 400 mg/ml + 5 mg/ml solution for injection for cattle
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains:
ACTIVE SUBSTANCES:
Florfenicol
400 mg
Meloxicam
5 mg.
EXCIPIENTS:
For the full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Solution for injection.
Clear yellow solution.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cattle.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For therapeutic treatment of bovine respiratory disease (BRD)
associated with pyrexia due to
_Mannheimia haemolytica_
,
_Pasteurella multocida _
and
_Histophilus somni_
susceptible to florfenicol.
4.3
CONTRAINDICATIONS
Do not use in adult bulls intended for breeding.
Do not use in animals suffering from impaired hepatic, cardiac or
renal function and haemorrhagic
disorders, or when there is evidence of ulcerogenic gastrointestinal
lesions.
Do not use in case of hypersensitivity to the active substances or to
any of the excipients.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
Whenever possible, the veterinary medicinal product should only be
used based on susceptibility
testing. Official, national and regional antimicrobial policies should
be taken into account when the
veterinary medicinal product is used.
Avoid use in severely dehydrated, hypovolaemic or hypotensive animals,
as there may be a potential
risk of renal toxicity. In the absence of safety data it is not
recommended to use the product in calves
less than 4 weeks old.
3
Special precautions to be taken by the person administering the
veterinary medicinal product to
animals
The product is slightly irritant to the eye. Rinse any splashes from
eyes immediately with plenty of
water.
In case of accidental self-injection, seek medical advice immediately
and show the package leaflet or
the label to the physician.
People with known hypersensitivity to florfenicol, meloxicam or to any
of th
                                
                                Baca dokumen lengkapnya
                                
                            

Dokumen dalam bahasa lain

Selebaran informasi Selebaran informasi Bulgar 30-05-2017
Karakteristik produk Karakteristik produk Bulgar 30-05-2017
Laporan Penilaian publik Laporan Penilaian publik Bulgar 30-05-2017
Selebaran informasi Selebaran informasi Spanyol 30-05-2017
Karakteristik produk Karakteristik produk Spanyol 30-05-2017
Laporan Penilaian publik Laporan Penilaian publik Spanyol 30-05-2017
Selebaran informasi Selebaran informasi Cheska 30-05-2017
Karakteristik produk Karakteristik produk Cheska 30-05-2017
Laporan Penilaian publik Laporan Penilaian publik Cheska 30-05-2017
Selebaran informasi Selebaran informasi Dansk 30-05-2017
Karakteristik produk Karakteristik produk Dansk 30-05-2017
Laporan Penilaian publik Laporan Penilaian publik Dansk 30-05-2017
Selebaran informasi Selebaran informasi Jerman 30-05-2017
Karakteristik produk Karakteristik produk Jerman 30-05-2017
Laporan Penilaian publik Laporan Penilaian publik Jerman 30-05-2017
Selebaran informasi Selebaran informasi Esti 30-05-2017
Karakteristik produk Karakteristik produk Esti 30-05-2017
Laporan Penilaian publik Laporan Penilaian publik Esti 30-05-2017
Selebaran informasi Selebaran informasi Yunani 30-05-2017
Karakteristik produk Karakteristik produk Yunani 30-05-2017
Laporan Penilaian publik Laporan Penilaian publik Yunani 30-05-2017
Selebaran informasi Selebaran informasi Prancis 30-05-2017
Karakteristik produk Karakteristik produk Prancis 30-05-2017
Laporan Penilaian publik Laporan Penilaian publik Prancis 30-05-2017
Selebaran informasi Selebaran informasi Italia 30-05-2017
Karakteristik produk Karakteristik produk Italia 30-05-2017
Laporan Penilaian publik Laporan Penilaian publik Italia 30-05-2017
Selebaran informasi Selebaran informasi Latvi 30-05-2017
Karakteristik produk Karakteristik produk Latvi 30-05-2017
Laporan Penilaian publik Laporan Penilaian publik Latvi 30-05-2017
Selebaran informasi Selebaran informasi Lituavi 30-05-2017
Karakteristik produk Karakteristik produk Lituavi 30-05-2017
Laporan Penilaian publik Laporan Penilaian publik Lituavi 30-05-2017
Selebaran informasi Selebaran informasi Hungaria 30-05-2017
Karakteristik produk Karakteristik produk Hungaria 30-05-2017
Laporan Penilaian publik Laporan Penilaian publik Hungaria 30-05-2017
Selebaran informasi Selebaran informasi Malta 30-05-2017
Karakteristik produk Karakteristik produk Malta 30-05-2017
Laporan Penilaian publik Laporan Penilaian publik Malta 30-05-2017
Selebaran informasi Selebaran informasi Belanda 30-05-2017
Karakteristik produk Karakteristik produk Belanda 30-05-2017
Laporan Penilaian publik Laporan Penilaian publik Belanda 30-05-2017
Selebaran informasi Selebaran informasi Polski 30-05-2017
Karakteristik produk Karakteristik produk Polski 30-05-2017
Laporan Penilaian publik Laporan Penilaian publik Polski 30-05-2017
Selebaran informasi Selebaran informasi Portugis 30-05-2017
Karakteristik produk Karakteristik produk Portugis 30-05-2017
Laporan Penilaian publik Laporan Penilaian publik Portugis 30-05-2017
Selebaran informasi Selebaran informasi Rumania 30-05-2017
Karakteristik produk Karakteristik produk Rumania 30-05-2017
Laporan Penilaian publik Laporan Penilaian publik Rumania 30-05-2017
Selebaran informasi Selebaran informasi Slovak 30-05-2017
Karakteristik produk Karakteristik produk Slovak 30-05-2017
Laporan Penilaian publik Laporan Penilaian publik Slovak 30-05-2017
Selebaran informasi Selebaran informasi Sloven 30-05-2017
Karakteristik produk Karakteristik produk Sloven 30-05-2017
Laporan Penilaian publik Laporan Penilaian publik Sloven 30-05-2017
Selebaran informasi Selebaran informasi Suomi 30-05-2017
Karakteristik produk Karakteristik produk Suomi 30-05-2017
Laporan Penilaian publik Laporan Penilaian publik Suomi 30-05-2017
Selebaran informasi Selebaran informasi Swedia 30-05-2017
Karakteristik produk Karakteristik produk Swedia 30-05-2017
Laporan Penilaian publik Laporan Penilaian publik Swedia 30-05-2017
Selebaran informasi Selebaran informasi Norwegia 30-05-2017
Karakteristik produk Karakteristik produk Norwegia 30-05-2017
Selebaran informasi Selebaran informasi Islandia 30-05-2017
Karakteristik produk Karakteristik produk Islandia 30-05-2017
Selebaran informasi Selebaran informasi Kroasia 30-05-2017
Karakteristik produk Karakteristik produk Kroasia 30-05-2017
Laporan Penilaian publik Laporan Penilaian publik Kroasia 30-05-2017

Peringatan pencarian terkait dengan produk ini

Lihat riwayat dokumen